GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mochida Pharmaceutical Co Ltd (TSE:4534) » Definitions » Return-on-Tangible-Equity

Mochida Pharmaceutical Co (TSE:4534) Return-on-Tangible-Equity : 5.08% (As of Dec. 2023)


View and export this data going back to 1963. Start your Free Trial

What is Mochida Pharmaceutical Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Mochida Pharmaceutical Co's annualized net income for the quarter that ended in Dec. 2023 was 円6,424 Mil. Mochida Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Dec. 2023 was 円126,508 Mil. Therefore, Mochida Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 5.08%.

The historical rank and industry rank for Mochida Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:

TSE:4534' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.37   Med: 7.85   Max: 10.92
Current: 2.37

During the past 13 years, Mochida Pharmaceutical Co's highest Return-on-Tangible-Equity was 10.92%. The lowest was 2.37%. And the median was 7.85%.

TSE:4534's Return-on-Tangible-Equity is ranked worse than
60.77% of 938 companies
in the Drug Manufacturers industry
Industry Median: 6.475 vs TSE:4534: 2.37

Mochida Pharmaceutical Co Return-on-Tangible-Equity Historical Data

The historical data trend for Mochida Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mochida Pharmaceutical Co Return-on-Tangible-Equity Chart

Mochida Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.76 6.97 8.31 5.24 3.59

Mochida Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.49 5.34 3.63 5.08 0.32

Competitive Comparison of Mochida Pharmaceutical Co's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mochida Pharmaceutical Co's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Mochida Pharmaceutical Co's Return-on-Tangible-Equity falls into.



Mochida Pharmaceutical Co Return-on-Tangible-Equity Calculation

Mochida Pharmaceutical Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=4547/( (125976+127244 )/ 2 )
=4547/126610
=3.59 %

Mochida Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=6424/( (126568+126448)/ 2 )
=6424/126508
=5.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Mochida Pharmaceutical Co  (TSE:4534) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Mochida Pharmaceutical Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Mochida Pharmaceutical Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Mochida Pharmaceutical Co (TSE:4534) Business Description

Traded in Other Exchanges
N/A
Address
1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.

Mochida Pharmaceutical Co (TSE:4534) Headlines

No Headlines